ABSTRACT: Background. The underlying contributors to cardiovascular disease (CVD) in patients with head and neck squamous cell carcinoma (HNSCC) are poorly characterized. Methods. Patients with HNSCC who underwent definitive or adjuvant (chemo)radiation between 2011 and 2013 were retrospectively reviewed. The 10-year risk estimates for a CVD event were calculated according to the Framingham Risk Score (FRS). Results. One hundred fifteen patients with predominantly stage III/IV HNSCC had a median follow-up of 2 years. At diagnosis, 23% of patients had CVD. The FRS was higher among patients with laryngeal cancer versus other sites (20.5% vs 14.4%). Twenty-four percent of all patients had uncontrolled blood pressure at diagnosis. Among the patients with CVD, 41% were not taking antiplatelet therapy and 30% were not taking statin therapy. Thirty-four percent of patients without CVD had indications for initiating statin therapy. Conclusion. Patients with HNSCC have a high baseline CVD risk and many do not receive optimal preventive care.
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) is diagnosed in 42,440 Americans every year. 1 The 5-year survival improved from 55% to 66% over the last 30 years 2 because of advances in multimodality therapy, including radiotherapy (RT), chemotherapy, and surgery, [3] [4] [5] as well as the increasing incidence of human papillomavirus (HPV)-related HNSCC, which responds better to therapy. 6 More than half of the deaths after treatment for HNSCC are now due to causes other than recurrent cancer. 7, 8 Patients with HNSCC have an elevated risk of non-HNSCC mortality that persists over their lifetime. Among patients with HNSCC, the 5-year incidence of HNSCC-specific mortality is 23.8%, second cancer mortality is 14.6%, and noncancer mortality is 13%. 9 The most frequent causes of noncancer mortality were coronary artery disease (28%), chronic obstructive pulmonary disease (8.5%), and cerebrovascular disease (5.6%). Between 5 and 10 years after treatment, HNSCC-specific mortality dramatically decreased to 5%, 10 whereas death because of second cancers and noncancer causes remained 20% to 25% higher in patients with HNSCC compared with matched controls. 11 Previous work demonstrates that RT increases the risk for carotid artery stenosis, 12, 13 which can lead to a stroke in 12% to 34% of patients with HNSCC. [14] [15] [16] RT-related carotid stenosis is difficult to treat; patients with HNSCC who develop carotid stenosis have a higher rate of progression (66% vs 5% per year) 12, 17 and restenosis after stenting (88% vs 27% over 2 years) compared to the general population. 12, 18 It is unclear to what degree preexisting conditions and/ or modifiable risk factors both before and after treatment contribute to cardiovascular disease (CVD), including heart attack and stroke. As such, we sought to quantify CVD risk and receipt of primary preventive care among patients with HNSCC treated with RT or chemoradiotherapy (CRT) at our institution. 
MATERIALS AND METHODS
This institutional review board-approved study retrospectively reviewed all patients with HNSCC treated with RT from the beginning of 2011 to the end of 2013. Inclusion criteria were defined as patients with HNSCC undergoing definitive or adjuvant (chemo)radiation with curative intent, a population known to have high rates of morbidity and mortality because of CVD. 9, 14 Patients treated for recurrent or metastatic HNSCC were excluded. Depending on stage and presentation, some patients received concurrent chemotherapy and/or surgery in addition to RT. After completing treatment, patients were evaluated every 2 to 3 months for the first 24 months, every 4 to 6 months for the next 3 years, and annually after 5 years.
Demographics were obtained at the time of diagnosis. Median household income was estimated based on zip code using the American Community Survey. 19 Data regarding risk, treatment, and primary prevention of CVD were collected and analyzed at 2 separate time points, pre-RT and post-RT. Pre-RT data were collected from records available at the time of HNSCC diagnosis; post-RT data were collected at the time of the most recent follow-up visit. In order to minimize the influence of the acute side effects of RT on CVD measures, post-RT data were only collected from patients having longer than 1 year of follow-up time without cancer recurrence. All patients had oncology-specific medical records and patient-reported medical histories available for review. Some patients additionally had records available from primary care providers (PCPs). Documented CVD of the coronary, carotid, or peripheral arteries was noted. For each patient, the 10-year risk estimate for developing a CVD event was calculated based on the Framingham Point Score (FPS), per 2001 guidelines from the Adult Treatment Panel III (ATP III), 20 and the Framingham Risk Score (FRS), per 2013 guidelines from the American College of Cardiology (ACC)/American Heart Association (AHA). 21 These scores incorporate information regarding sex, age, race, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, diabetes mellitus, current smoking, and use of antihypertensive therapy. We relied on patient reports of smoking habits to categorize those who were active smokers and to calculate the number of pack-years smoked. When serum cholesterol values were not available in the medical record, optimal levels were assumed. 21 The average of 3 readings for systolic blood pressure was used to calculate the Framingham scores. 22 In addition, patients were categorized as high, intermediate, or low-risk for cardiovascular events based on the ATP III classification. 20 Finally, medications and dosages, including antihypertensives, antiplatelets, statins, and diabetes drugs were recorded.
Assessment of the quality of CVD prevention included the management of diabetes mellitus and blood pressure, as well as the prescription of statin therapy. Uncontrolled diabetes mellitus was defined as hemoglobin A1c >7%, random total glucose >200 mg/dL, or fasting glucose 126 mg/dL. 22, 23 Blood pressure was considered uncontrolled if values were >140/90 at 2 or more clinic visits per recommendations of the Joint National Committee; either abnormal systolic and/or diastolic values were considered in this assessment. 24 Appropriate statin prescription was based on CVD prevention guidelines from the ATP III or the ACC/AHA. Both guidelines base recommendations for statin use on serum cholesterol levels and/or the presence of additional CVD risk factors. The ACC/AHA advocates for patients with an AHA FRS 7.5% to engage in a discussion with their physician to consider initiating statin therapy. Additionally, for patients with a known diagnosis of CVD, secondary preventive measures, including statins and antiplatelet medications, were recorded.
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T tests were used to determine associations between the group levels of demographic and cancer-specific factors and AHA FRS, whereas Fisher's exact tests determined whether they associated with suboptimal management of diabetes mellitus, blood pressure, or hypercholesterolemia. We also hypothesized that suboptimal management of CVD risk factors would decrease from pre-RT to post-RT time points. In support of this hypothesis, previous studies describe cancer diagnosis as a teachable moment, when there is an opportunity to promote positive health behavioral change, such as smoking cessation in patients with HNSCC. 26, 27 McNemar's test compared the proportion with suboptimal management before versus after radiation. Statistical analysis was completed using SAS software, version 9.2 of the SAS System for Windows (SAS Institute, Cary, NC).
RESULTS

Patient and treatment characteristics
Two hundred eight patients were treated with RT for HNSCC between 2011 and 2013. Of these, the following patients were excluded: 8 with metastatic disease, 2 undergoing palliative treatment, 8 with recurrent disease, and 75 having nonsquamous cell carcinoma histology. In total, 115 patients were identified who met the inclusion criteria and constituted the subject of the present analysis.
Baseline patient and treatment characteristics are outlined in Table 1 . Median age was 63 years. The majority of patients were men, white, and married or living with a partner. Some patients had limitations in access to care: 12% of patients were uninsured at initial presentation, and 20% failed to identify a primary care provider (PCP). The bulk of diagnoses were clinical stage IV HNSCC of the oropharynx, larynx, or oral cavity per the seventh edition of the American Joint Committee on Cancer. 28 The median clinical follow-up time was 2 years (range, 0-3.7 years).
Cardiovascular disease risk assessment
At the time of diagnosis, the most prevalent CVD risk factor was hypertension (50%), followed by current smoking (27%), and diabetes mellitus (12%; Table 2 ). Twenty-seven patients had known CVD, including coronary artery disease (17 patients), peripheral vascular disease (5 patients), and carotid artery disease (10 patients), all diagnosed before treatment for HNSCC. There were no documented CVD events experienced by any patients during the short followup period after treatment.
Among the 88 patients without diagnosed CVD, the mean 10-year risk estimate for developing an atherosclerotic cardiovascular event was 9.8% (95% confidence interval [CI], 8.4-11.2) by the ATP III FPS and 13.2% (95% CI, 10.7-15.7) by the AHA FRS. Patients with laryngeal cancer had an AHA FRS of 20.5%, compared to 17.8% among those with HPV-negative oropharyngeal cancer and 14.7% for those with HPV-positive oropharyngeal cancer (Table  3) . Compared with patients with HPV-positive oropharyngeal cancer, more patients with HPV-negative oropharyngeal or laryngeal cancer were active smokers (58% vs 21%), had hypertension (58% vs 48%), poorly controlled blood pressure (33% vs 21%), or indications per statin therapy per AHA guidelines (80% vs 67%; Table 4 ). Among patients with HPV-positive oropharyngeal cancer with a 10 pack-year smoking history, 56% of patients had an AHA FRS 7.5%.
There were no significant differences in AHA FRS by sex, race, income, or educational status (Table 3) . Compared to before RT, similar numbers of patients were actively smoking after RT, as well as taking medications for hypertension or diabetes mellitus (Table 2) .
Cardiovascular disease prevention
Regardless of antihypertensive medication use, the proportion of patients with uncontrolled blood pressure was similar at pre-RT and post-RT time points (28 vs 26 patients; Table 2 ). Meanwhile, 4 patients had uncontrolled glucose levels in both the pre-RT and post-RT setting. A total of 39 patients and 26 patients were taking statins before and after RT, respectively. Among 27 patients with a history of CVD, 16 were not taking antiplatelet therapy and 8 were not taking statin therapy at baseline. An additional 10 patients with CVD should have been taking a higher intensity statin per ACC/AHA guidelines. Patients with CVD not taking statin therapy were less likely to identify a PCP than those taking a statin (4 of 8 patients vs 17 of 19 patients). Among 88 patients without CVD at baseline, 30 patients were not currently taking a statin, but had indications for therapy per ACC/AHA guidelines.
DISCUSSION
Our data demonstrate a high prevalence of and risk for CVD at the time of HNSCC diagnosis. Specifically, 15% of patients with HNSCC had coronary artery disease and 9% had carotid artery disease. In the general population, the prevalence of coronary artery disease and carotid artery disease increases from 6% and 2% among men aged 40 to 59 years old to 21% and 7% among men aged 60 to 79 years old, respectively. 29, 30 The proportion with CVD in the general population is similar to that among our patients with HNSCC, who were composed predominantly of men at a median age of 63 years old. However, many of the remaining patients with HNSCC without documented CVD had a high 10-year risk estimate for developing a CVD event, as quantified by an AHA FRS 7.5% (58% of patients with HNSCC vs 33% in the general population). 31 
Cardiovascular disease preventive care
In total, 63% of our patients would be recommended to take statin therapy per ACC/AHA guidelines. These complex patients often receive suboptimal preventive care; 20% to 30% of patients have uncontrolled blood pressure and 30% to 50% of patients with diabetes have uncontrolled blood glucose levels at both pre-RT and post-RT time points. If ACC/AHA guidelines were applied to this population, an additional 38% of patients would qualify either for initiation of statin therapy or use of a highintensity statin. In addition, many patients with HNSCC with known CVD received poor secondary preventive care with 59% not taking antiplatelet therapy and 30% not taking statin therapy. Unfortunately, poor secondary CVD preventive care has also been reported in survivors of lung, breast, colon, and renal cancer with less than half of the patients with CVD receiving guideline-directed medical therapy (including statins) or referrals to a cardiologist. 32 Predictors of cardiovascular disease risk and prevention Unfortunately, we have limited power to detect associations between AHA FRS and demographic or cancerspecific factors because of the small sample sizes of the subgroups. Not surprisingly, the FRS was the highest among our patients with laryngeal cancer, a subgroup known to have high mortality rates, 33 likely relating to older age and tobacco use. 10 However, significant CVD risk was not confined to patients with laryngeal cancer. Even among the subgroup of patients with HNSCC with the most favorable prognosis (HPV-positive oropharyngeal cancer with a 10 pack-year smoking history), 34 56% of patients have an AHA FRS 7.5% and, therefore, would be recommended to take statin therapy per guidelines. Therefore, it is important to consider CVD prevention among all HNSCC cancer types.
Limitations
Our study was subject to several limitations. There was information bias in retrospective studies given possible underreporting of CVD risk factors in the medical records. In addition, the calculated CVD risk estimates likely underestimated the true risk because we assumed optimal values for missing serum cholesterol data. Furthermore, it is not known whether CVD risk in HNSCC remains stable over time, especially after completing RT. We limited our post-RT analysis to patients with 1 year or more of follow-up time in order to minimize the effect of acute treatment toxicity on CVD risk. Finally, it is unclear whether the target goals for CVD risk reduction that have been established for the general population are applicable to patients facing a life-altering disease, such as HNSCC. However, because there were similar degrees of blood pressure control and statin use at both diagnosis and after 1 year of follow-up makes these results less likely to be spurious. Future study with more follow-up time is needed to determine how CVD risk and its management affect long-term cardiovascular outcomes in patients with HNSCC.
Future directions
In conclusion, patients with HNSCC have a high risk for CVD and often receive suboptimal preventive care. Strategies to minimize these risks are needed that involve primary care, oncology, and cardiology practitioners. As a first step, it is possible that the application of 2013 ACC/ AHA guidelines regarding statin therapy use may improve survival and quality of life in patients with HNSCC. The 2013 ACC/AHA guidelines recommend that patients with a 10-year cardiovascular risk 7.5% discuss initiating statin therapy with their physician, because the benefits of therapy are likely to outweigh the harms. 21 This recommendation for statin use is based on high-level evidence demonstrating a relative reduction in cardiovascular events of similar magnitude across a wide spectrum of CVD risk and serum cholesterol levels (rate ratio, 0.78; 95% CI, 0.76-0.81). 35 Future work should investigate whether these guidelines need to be adapted to the special needs of patients with HNSCC, who may have a higher risk for drug-drug interactions or competing mortality, barriers to shared decision-making, and/or greater carotid artery injury because of RT.
Additionally, future work should investigate whether statins or other drugs protect the carotid arteries from RTrelated injury. The hypothesis that statins reduce RTrelated carotid artery injury by lowering cholesterol levels is suggested by a clinical study that found that the degree of progression in carotid artery intima-media thickness after RT was associated with pre-RT low-density lipoprotein cholesterol levels (r 5 0.66; p 5 0.03). 36 If statins are found to be protective, this would lead to an expansion of the indications for statin use to include patients receiving head and neck RT with otherwise low CVD risk. Among our patients, approximately 33% had low CVD risk and would not otherwise be recommended to receive statin therapy.
